Purpose: We report the first family with PIGA-associated epileptic encephalopathy in Taiwan and hope to elucidate its special phenotype and inheritance pattern. Method: We found a Taiwanese family with several members suffered from severe epileptic encephalopathy (ZY07, ZY01, ZY04). To determine the underlying etiology, whole exome sequencing was conducted. Results: A single novel variant, NM_002641: c.356G > A, p.Arg119Gln, was identified in the X chromosome PIGA gene in our proband patient (ZY07). The patient's mother (ZY02) and aunt (ZY03) were confirmed as carriers of the hemizygous variant. Conclusions: This paper highlights the highly transmitted features of PIGA and other X-linked EIEEs, raising awareness of rare forms of epileptic encephalopathy.
Introduction
The phosphatidylinositol N-acetylglucosaminyltransferase subunit A (PIGA) gene located on chromosome Xp22.1 and its protein are involved in the first biosynthesis step of glycosylphosphatidylinositol (GPI) anchors in the plasma membrane [1] . GPI anchors are glycolipids that attach dozens of different proteins to a cell's surface. These GPI-anchored proteins have diverse functions for neurogenesis, complement regulation, and embryogenesis, and are associated with various disorders [2] . Somatic PIGA mutation is responsible for deficiency of GPI-anchored proteins in paroxysmal nocturnal hemoglobinuria [3] . Johnston et al. [2] were the first to report a germline PIGA mutation in a family with anomalies such as neonatal seizures, brain malformation, and facial dysmorphism. Subsequently, Kato et al. [4] conducted a functional analysis of seven cases of PIGA mutations and thus identified the PIGA gene associated with early infantile epileptic encephalopathy (EIEE). This paper reports details of a novel missense mutation of PIGA resulting in EIEE and is the first report of a family with PIGAassociated epileptic encephalopathy in Taiwan.
Case report
The proband patient ( Fig. 1: ZY07) was the third child of a pair of nonconsanguineous healthy parents. His mother had polyhydramnios during pregnancy and he was born at 33 + 6 weeks of gestation. His birth weight was 2685 g (+0.7 SD), his height was 42 cm (À1.4 SD), and his head circumference was 33.5 cm (AE0 SD).
The patient was admitted to our neonatal intensive care unit shortly after birth because of systemic cyanosis and muscular hypotonia. A general physical examination revealed facial dysmorphism in the form of a depressed nasal bridge, large mouth, high-arched palate, and micrognathia. The follow-up revealed that the patient had severe global developmental delay, axial hypotonia, and dyskinesia, including dystonia and chorea of the distal extremities (noticed at the age of 4 months).
Epileptic spasms and erratic myoclonic seizures were first noticed at the age of 2 months. At 3 months, his seizure semiology changed to repetitive episodes of thrashing of the extremities, frequent apnea, eye roving, and eyelid twitching. An interictal electroencephalogram (EEG) at 3 months revealed poor background formation and multiple focal spikes and waves ( Supplementary Fig. 1 ), and the patient was diagnosed with EIEE. An investigation into the family's history ( Fig.1 ) revealed that two other family members presenting with similar clinical manifestations, ZY01 (maternal granduncle of ZY07, second degree in the pedigree) and ZY04 (maternal cousin of ZY07, fourth degree in the pedigree), had died at the age of 2. The proband's two elder sisters, ZY05 and ZY06, are healthy girls with normal development. Thus, an X-linked inheritance pattern was suspected. Multiple antiepileptic drugs were administered, namely pyridoxine, folate, phenobarbital, levetiracetam, clobazam, valproic acid, lamotrigine, clonazepam, and topiramate. None of the AEDs were effective in treating his seizures, although levodopa (1 mg/kg/day) alleviated dyskinesia to some extent.
Comprehensive investigations included the following: urine organic acids; serum (sodium, glucose, calcium, magnesium, liver function, ammonia, lactate, pyruvate, amino acids); arterial blood gas, pH, lactate, and pyruvate; carnitine, acylcarnitine, and carbohydratedeficient transferring; biotinidase enzyme activity; toxicology screen; cerebrospinal fluid (lactate, amino acids, neurotransmitter profile, cell count and differential, glucose, total protein, herpes simplex virus type 1 or 2 polymerase chain reaction, gram stain, and culture); and mitochondrial mutation hot spots (mitochondrial DNA nt3243, 8344, 8993, 10191, and 13513). The results were all negative. Brain magnetic resonance imaging at 4 and 10 months of age revealed progressive brain atrophy, delayed myelination, and a thin corpus callosum ( Supplementary Fig. 2 ). Renal sonography at 7 months showed bilateral hydronephrosis. Additionally, an elevated level of alkaline phosphatase (405 IU/L) was detected during a series of tests. Therefore, whole exome sequencing (WES) was conducted to determine the underlying etiology.
DNA for WES was extracted from peripheral blood from index cases and their parents and stored at À80 C. To generate standard exome capture libraries, we used the Agilent SureSelectXT Reagent Kit protocol for the Illumina Hiseq paired-end sequencing library (catalog#G9611A), and raw reads were mapped to the reference human genome (UCSC Genome Browser-hg19; University of California, Santa Cruz, CA, USA) by using BWA version 0.6.5a.
A SureSelectXT Human All Exon Version 6 (51 Mb) probe set was used. Fifty nanograms of genomic DNA was employed to construct the library with the Agilent SureSelectXT Reagent Kit. The amplification-adapter-ligated sample was purified using Agencourt AMPure XP beads (Beckman Coulter, Brea, CA, USA) and analyzed using a Bioanalyzer DNA1000 chip. From the sample, 750 ng was prepared for hybridization with capture baits, and the sample was hybridized for 90 min at 65 C, captured using Dynabeads My One Streptavidin T1 (Life Technologies, USA), and purified using Agencourt AMPure XP beads. The Agilent protocol was adopted for the addition of index tags through posthybridization amplification. Finally, the sample was sequenced on an Illumina NextSeq500 by using the 150PE protocol. All samples passed quality control criteria, and over 99% of the targeted capture region was covered at 10.
Variant calling was performed using the recommended best practices of GATK version1.0.5506 (Broad Institute). Variant annotation and prioritization were performed using a welldeveloped pipeline, wANNOVAR [5] . A few commonly used functional annotations, such as different types of gene annotation, the alternative allele frequency in the 1000 Genomes Project, conserved element annotation, dbSNP annotation, deleteriousness prediction scores for nonsynonymous variants, ClinVar variant annotation, and genome-wide association study variant annotation, are included in the results [6] .
Moreover, we implemented a variant-reduction pipeline; variants such as synonymous variants, variants with a frequency of <10%, and variants with an allele frequency of >1% were removed. Standard pathogenicity prediction programs, including PolyPhen2, SIFT, and Mutation Taster (http://www.mutationtaster.org/), were used [7] .
Only a single novel variant, namely NM_002641: c.356G > A, p. Arg119Gln, was identified in the X-chromosome PIGA gene. Sanger sequencing of a DNA sample confirmed the variant in the patient ( Fig. 2A: ZY07 ), his mother (Fig. 2B: ZY02) , and his aunt. This variant is not present in the 1000 Genomes Project. The patient's mother (ZY02) and aunt (ZY03) were confirmed to be carriers of the heterozygous variant. According to the standards and guidelines of the American College of Medical Genetics and Genomics [8] , this variant is pathogenic (Supplementary Table 1) . 
Discussion
A novel PIGA variant (c.356G > A: p. Arg119Gln) was detected through exome sequencing. To our knowledge, this is the 14th reported case of PIGA epileptic encephalopathy [9] . The PIGA phenotype can be classified as "severe" and "less severe" depending on the degree of GPI protein dysfunction. According to previous publications [4, [9] [10] [11] [12] Although WES was performed, we focused on gene mutations detected in the X chromosome because we suspected an X-linked inheritance pattern. Finally, we detected the PIGA gene. In addition to PIGA, the genes currently known to be associated with X-linked early infantile epileptic encephalopathy are CDKL5 (XLD Notably, in this study, the patient's aunt (ZY03, heterozygous PIGA variant carrier) was a 26-year-old adult with a healthy mental status. However, she was diagnosed with idiopathic epilepsy at the age of 12 and is currently still being treated with antiepileptic drugs. Further research is required to determine whether her epilepsy suggests X-linked PIGA inactivation.
In conclusion, this paper provides the first report of a family with a PIGA mutation in Taiwan that underscores the diverse phenotypes of the PIGA gene. Furthermore, it highlights the frequently transmitted features of PIGA and other X-linked EIEEs, raising awareness of these rare forms of epileptic encephalopathy.
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